Fed. Circ. Mulls Amgen-Sandoz Psoriasis Drug Dispute
By Nadia Dreid ( February 8, 2023, 8:57 PM EST) -- The Federal Circuit spend part of its morning Wednesday parsing the definition of "a difference in degree not in kind" in order to decide whether a lower court had erred by tossing out two Amgen patents covering a plaque psoriasis medication but leaving two others that create a "patent estate" around the medication....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.